Original Article

Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride

Raquel Ramos Garcia¹, Khalid Z Masoodi¹, Laura E Pascal¹, Joel B Nelson¹,³, Zhou Wang¹,²,³

¹Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh PA 15232, USA; ²Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA; ³University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA

Received March 26, 2014; Accepted March 30, 2014; Epub April 5, 2014; Published April 15, 2014

Abstract: Intermittent androgen deprivation therapy (IADT) allows prostate cancer patients a break from the side-effects of continuous androgen deprivation therapy (ADT). Although clinical studies suggest that IADT can significantly improve patient quality of life over ADT, it has not been demonstrated to improve patient survival. Recently, increased survival has been demonstrated when 5α-reductase inhibitors have been used during the off-cycle of IADT in animal xenograft tumor models LNCaP and LuCaP35. In the current study, the sensitivity of LAPC4 xenograft tumor regrowth to the 5ARI dutasteride was determined. Tumor regrowth and gene expression changes in LAPC4 tumors were compared to the previously determined response of LNCaP and LuCaP35 xenograft tumors to 5ARI treatment during the off-cycle of IADT. LAPC4 tumors were compared to the previously determined response of LNCaP and LuCaP35 xenograft tumors to 5ARI treatment during the off-cycle of IADT. LAPC4, LNCaP and LuCaP35 tumors were sensitive to androgen manipulation. However, in contrast to LNCaP and LuCaP35, dutasteride treatment during testosterone-stimulated prostate regrowth did not affect tumor regrowth or the expression of androgen responsive genes. Tumor response to dutasteride during the off-cycle of IADT is variable in xenograft prostate tumor models. Future studies will be required to elucidate the mechanisms contributing to the dutasteride resistance observed in the LAPC4 model during the off-cycle.

Keywords: Prostate cancer, androgen deprivation therapy, LAPC4, EAF2, 5α-reductase inhibitor

Introduction

Intermittent androgen deprivation therapy (IADT) has been proposed as an alternative treatment for prostate cancer in an effort to decrease the complications associated with continuous androgen deprivation therapy (ADT). ADT is associated with several side-effects including loss of libido, hot flashes, anemia, fatigue, loss of muscle and bone mass as well as endocrine and metabolic abnormalities (reviewed in [1]). IADT consists of multiple cycles of androgen suppression (on-cycle) and periods of testosterone recovery (off-cycle), where PSA and other clinical markers, are used to guide off-cycle duration. In several clinical trials, IADT has been shown to significantly reduce the side-effects associated with continuous ADT [2-7]. A majority of prostate cancer patients with sexual side effects reported an increased sexual activity and well-being during IADT [6, 8]. Some preclinical studies have also suggested that IADT might delay prostate tumor progression to castration resistance. IADT was shown to prolong the time to androgen-independent PSA regulation in LNCaP xenografts [9]. In the Shinogi tumor model, IADT induced a 3-fold delay in progression to androgen independence [10]. However, the impact of IADT on prostate cancer progression and survival in clinical trials is less clear. Several randomized controlled trials failed to demonstrate a statistically significant difference in survival between IADT and ADT in patients [3, 11-15]. Moreover, a recent large trial of 1535 men reported that IADT was associated with decreased survival compared to ADT in metastatic prostate cancer [16]. In a recent meta-analysis study comparing the efficacy of IADT versus ADT with respect to all-cause and disease-specific mortality, there was no difference in overall survival, but a small increased risk in disease-specific survival for men treated with IADT relative to ADT [17].
Dutasteride in LAPC4 prostate tumor regrowth

In an effort to maximize the potential benefits of IADT, the addition of 5α-reductase inhibitors (5ARI) has also been proposed. The regressed prostate responds differently to 5ARI treatment, which blocks the conversion of testosterone to DHT, than the intact prostate. 5ARI treatment in testes-intact rats reduced the expression of androgen-responsive genes [18], whereas addition of 5ARI during testosterone-stimulated prostate regrowth after castration increased androgen-responsive gene expression [19]. Addition of 5ARI to the off-cycle increased survival over IADT alone in LNCaP xenografts when the off-cycle interval was fixed [20]. However, when the off-cycle was terminated based on a pre-determined tumor volume, 5ARI treatment doubled the off-cycle interval but had no effect on survival [21]. We recently demonstrated that 5ARI treatment in LuCaP35 and LNCaP xenograft tumors suppressed initial regrowth of regressed prostate tumors, suggesting that a short off-cycle plus 5ARI treatment could maximize prostate tumor growth suppression and potentially prolong survival [22].

Prostate tumors are highly heterogeneous and variability among patients is great, which adds to the complexity of treating prostate cancer. Androgen-sensitive prostate cancer cell line models also have distinct differences and experimental results across various cell lines can vary widely. The androgen receptor in the most frequently used androgen-sensitive prostate cancer cell line, LNCaP, contains a single point mutation which has been shown to affect both binding specificity and the induction of gene expression [23]. LuCaP35 is an androgen-sensitive, PSA producing xenograft that was derived from a prostate cancer lymph node metastasis and expresses the wild-type androgen receptor [24]. In the current study, the effects of dutasteride on gene expression during testosterone stimulated prostate tumor regrowth were examined in the androgen-sensitive LAPC4 xenograft tumor model. LAPC4 is a more recently developed prostate cancer cell line derived from a lymph node metastasis that expresses wild-type AR and secretes PSA [25]. Understanding the variation in tumor response to IADT and ADT across multiple prostate cancer xenograft models will provide critical insight for maximizing the benefits of IADT across various prostate cancer patients in the clinical setting.

Materials and methods

Animals

BALB/c strain of athymic SCID and Hsd: Athymic Nude-Foxn1nu strain of nude male mice were obtained from Charles River Laboratory, Wilmington, MA and Harlan labs, Indianapolis, IN respectively and were kept in accordance with the National Institute of Health guidelines under standard animal housing conditions for the Care and Use of Experimental Animals. Animal experiments were approved by the Institutional Animal Care Use Committee (IACUC) at the University of Pittsburgh.

Xenograft tumor implantation

The LAPC4 cell line, which produces PSA, has wild-type androgen receptor, and shows features of hormone-dependent growth and metastasis [25], was a gift from Charles Sawyers, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA and Robert Reiter, Department of Urology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. LAPC4 were maintained in IMDM, supplemented with 10% fetal bovine serum (FBS), glutamine, penicillin and streptomycin. LAPC4 cells underwent 4-8 passages in culture prior to mouse inoculation. Approximately 10⁶ LAPC4 cells suspended in 250 μL media were mixed 1:1 with Matrigel (Becton Dickinson Labware, Bedford, MA) and then inoculated subcutaneously in the flank region of 6~8 week old male athymic SCID/Nude mice using a 25-gauge needle as previously described for LNCaP and LuCaP35 tumors [21, 22].

Construction of testosterone and dutasteride pellets

Pellets were prepared as previously described [21, 22]. Approximately 7.5 mg of testosterone (Sigma Chemical, St. Louis, MO) was tightly packed into a silastic tube with an inner and outer diameter of 1.58 mm and 3.18 mm, respectively (Helix Medical, Carpenteria, CA). Dutasteride (gift from GlaxoSmithKline) and pellets were made similarly; ~8 mg of dutasteride was packed into silicone tubing with an inner and outer diameter of 1.47 mm and 1.96 mm, respectively. Pellet ends were plugged with wooden sticks and sealed with a silicone
Dutasteride in LAPC4 prostate tumor regrowth

**Figure 1.** Experimental protocols. Tumor bearing nude mice were castrated and subjected to 2 different protocols, castrated (C) and testes-intact (I). Castrated animals were further randomized into 4 subgroups: implantation of testosterone (C+T), dutasteride (C+D), testosterone + dutasteride (C+T+D), and no intervention (C). Testes-intact animals were randomized into 2 subgroups: testes-intact (I) and testes-intact + dutasteride (I+D). Testosterone and/or dutasteride pellets were implanted on day 14 post-castration. Animals were euthanized and tumors were collected at day 18 and day 28 post-castration.

adhesive (Dow Corning, Midland, MI). Following overnight air-drying, pellets were sterilized with 70% ethanol for 10 min and stored in a light-free environment.

*Treatment protocol and measurement of tumor growth and gene expression*

The experimental design is outlined in Figure 1. Tumors were measured weekly and volume was calculated by the modified ellipsoid formula: length x width$^2$ x 0.52 [26]. For the castration group, trans-scrotal castration was performed under isoflurane anesthesia with proper aseptic and antiseptic technique as previously [21]. Mice were initially randomized into two groups, testes-intact (I) and castration (C), when xenograft tumors reached a volume of 200 mm$^3$. Mice were treated using 2 different protocols as either castrated (C) or testes-intact (I) (Figure 1A). Castrated mice were randomized 14 days post-castration into 4 groups: 1) cas-
Dutasteride in LAPC4 prostate tumor regrowth

85

Am J Clin Exp Urol 2014;2(1):82-91

1) castration only (C), 2) castration + testosterone replacement (C+T), 3) castration + testosterone replacement + dutasteride (C+T+D), and 4) castration + dutasteride (C+D). Testes-intact mice were randomized on the same time schedule as castrated mice into 2 groups: intact (I), and intact + dutasteride (I+D). After randomization, all groups were followed for either 18 or 28 days (Figure 1B). Animals in the castration (C) and intact (I) groups were followed without any further intervention. Testosterone and/or dutasteride pellets were surgically implanted subcutaneously 14 days post-castration in the groups receiving additional treatment (Figure 1B). Tumor volume was measured every 2 days. Tumors were collected at day 18 or day 28, either 4 days or 14 days after pellet implant. Each experimental group consisted of 5-6 animals and tumors were collected at sacrifice and flash-frozen in liquid nitrogen for further analyses.

Androgen sensitivity was assessed as a statistically significant decrease in tumor volume in castrated compared to testes-intact animals within the first 14 days post-castration. Tumors that continued to grow within the 14 day period after castration were considered castration resistant and were excluded, as this study was designed to assess the ability of IADT coupled with 5ARI to inhibit tumor growth in LAPC4 xenograft tumor model.

Gene expression analysis

Quantitative real time reverse-transcriptase polymerase chain reaction (qPCR) was used to determine gene expression. Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA). Approximately 2 μg of RNA was reverse transcribed with random primers using the high capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). Exon-exon junction spanning primers and Taqman probes were designed using Primer 3 software (Totowa, NJ) and synthesized by Integrated DNA Technologies (Coralville, IA). Primers used were: calreticulin For: 5'-GGATCGAATCCAAACACAAGTC-3', Rev: 5'-TGGCTTTGTCTGCAAACCTTTAT-3'; EAF2/U19 For: 5'-CCAGGACTCCCAATCTTGTAAA-3', Rev: 5'-TAGCTTCTGCTTCCAGTTCTCTT-3'; ELL2 For: 5'-TGACTGCAATCCAGCAAAACAT-3', Rev: 5'-TCGTGGTTGCACACACTGTA-3'; PSA For: 5'-GTCCGGGTGTCTTCCTCTC-3', Rev: 5'-CACAACTCCGAAGGATGAG-3'. Ex Taq™ 2X premix (Takara Bio Inc.) was used for real time PCR reactions with 0.25 μM of forward and reverse primers each. Reactions were run in triplicate on a Bio-Rad IQ5 (Bio-Rad Laboratories, Hercules, CA), and repeated on an ABI Step-One Plus (Applied Biosystems, Foster City, CA). ROX was used as passive reference dye. Glyceralddehyde-3-phosphate dehydrogenase (GAPDH) served as endogenous control, primer GAPDH: 5'-CATGTTGCATGGGTGTGA-3', Rev: 5'-GGTGCTAAGCAGTTGGTGGT-3'. The specificity of the primer-probe combinations for their cDNA targets was confirmed by lack of amplification of human genomic DNA, mouse genomic DNA or mouse cDNA. qPCR data were exported into MS Excel and the expression of transcripts relative to GAPDH calculated by the ΔCP method: Relative Expression = 2^ΔCP, where ΔCP is the difference between the crossing point thresholds of target gene versus GAPDH, as described previously [27].

Figure 2. Response of LAPC4 xenograft tumors to androgen manipulation. A. Tumor volume in testes-intact (I) and castrated (C) at day 0 and day 14 post-castration. Values expressed as percentage of original volume (200 mm^3). B. Response of LAPC4 tumors to 4 days of treatment. Tumor volume at day 0, day 14 and day 18 post-castration (4 days after pellet implant). Testes-intact (I), testes-intact plus dutasteride (I+D), castrated (C), castrated with testosterone replacement (C+T), castrated + dutasteride (C+D), castrated + testosterone replacement + dutasteride (C+T+D). Number of animals in each group is listed in parentheses. Values are expressed as mean ± SEM. (*, P < 0.05; **, P < 0.01).
Dutasteride in LAPC4 prostate tumor regrowth

Statistical analysis

GraphPad Prism 5.0 (GraphPad Software, Inc) and MS Excel 2003 (Microsoft) were used for statistical analysis and graphical composition. Data were expressed as the mean ± SEM, and statistical significance was determined by one-way ANOVA or Student’s t-test as appropriate. A P value of < 0.05 was considered statistically significant. The results were depicted on scatter plots to convey the expression patterns.

Results

LAPC4 xenograft tumors were sensitive to androgen manipulation

LAPC4 xenograft tumor volume in castrated animals (C) was significantly decreased compared to intact control animals (I) by day 14 post-castration, verifying the androgen sensitivity of LAPC4 xenograft tumors (Figure 2A). Intact animals displayed a steady growth increase to 140% of the original volume over 14 days, whereas tumor volume in castrated animals was reduced significantly by 20% by day 14 (**P < 0.01) (Figure 2A).

In the LuCaP35 and LNCaP xenograft models, tumors in castrated animals treated with testosterone rapidly increased in volume within the first 4 days of testosterone replacement [22]. LuCaP35 and LNCaP xenograft tumor growth in castrated animals treated with testosterone plus dutasteride or finasteride was significantly inhibited during the first 4 days of treatment [22]. In contrast, LAPC4 xenografts in castrated animals treated with testosterone did not increase in volume during the first 4 days of treatment (Figure 2B). Furthermore, LAPC4 tumor growth was not significantly inhibited during the first 4 days of treatment with testosterone plus dutasteride or testosterone alone (p > 0.05). These findings suggested that although LAPC4 tumor growth is sensitive to castration, testosterone-stimulated response of regressed tumors differs from that of LNCaP or LuCaP35.

Dutasteride treatment had no effect on PSA, EAF2, CALR or ELL2 expression in LAPC4 xenograft after 4 days of testosterone replacement

Previous studies have demonstrated that dutasteride treatment during testosterone stimulated regrowth enhanced the expression of several androgen response genes, including EAF2 in the LNCaP [18] and LuCaP35 [22] xenograft models. Androgen responsive gene up-regulation was accompanied by a repression in growth of LNCaP and LuCaP35 xenograft tumors during the off-cycle when dutasteride
was added. These studies suggested that short off-cycles coupled with 5α-reductase inhibition could suppress prostate tumor growth, potentially contributing to increased survival. In the current LAPC4 xenograft model, although PSA transcript level decreased significantly following castration and increased in response to testosterone replacement, dutasteride treatment alone had no significant effect (Figure 3A). Castrated animals treated with testosterone had a statistically significant increased expression of PSA compared to castrated controls. Castrated animals treated with testosterone replacement and dutasteride had a statistically significant increased expression in PSA over dutasteride treatment alone (C+D). However, in contrast to the previous findings in the LNCaP and LuCaP35 models [18, 22], in castrated animals treated with testosterone plus dutasteride for 4 days, PSA expression was similar to testosterone replacement alone. Although not statistically significant, EAF2 expression was also increased in response to testosterone replacement in castrated animals (p=0.15), as

Figure 4. Effect of dutasteride on LAPC4 tumor regrowth 14 days after pellet implantation (day 28). A. Effect of dutasteride on LAPC4 tumor volume. Tumor volume in intact (I), intact + dutasteride (I+D), castrated with testosterone replacement (C+T), castrated + testosterone replacement + dutasteride (C+T+D) was determined at day 28 post-castration. Values are presented as mean ± SEM. Number of animals in each group is represented in parentheses. B. Response of androgen-sensitive xenograft tumors LAPC4, LuCaP35 and LNCaP to 5α-reductase inhibition during testosterone stimulated regrowth after 4 days of treatment (day 18). Tumor volume in castrated animals treated with testosterone (C+T) and testosterone plus dutasteride (C+T+D) for 4 days or finasteride (C+T+F) for 4 days. C. Response of androgen-sensitive xenograft tumors LAPC4, LuCaP35 and LNCaP to 5α-reductase inhibition during testosterone stimulated regrowth after 14 days of treatment (day 28). Tumor volume in castrated animals treated with testosterone (C+T) and testosterone plus dutasteride (C+T+D) for 14 days or finasteride (C+T+F) for 10 days. Data from LuCaP35 and LNCaP derived from previously published data [18, 22]. Number of animals in each group is represented in parentheses. (*, P < 0.05).
Dutasteride treatment did not inhibit LAPC4 xenografts tumor growth

LAPC4 tumor growth rate in both testes-intact animals as well as castrated animals with testosterone replacement was not altered by dutasteride treatment (Figures 2B and 4A). Although androgen-responsive gene expression was up-regulated during the initial phase of regrowth in regressed LAPC4 xenograft tumors, tumor growth was not affected by 5ARI during the off-cycle in this model. The overall change in tumor volume after 14 days of treatment was not significantly different between castrated animals treated with dutasteride during testosterone replacement (C+T+D) and testosterone alone (C+T). In comparison, previous findings demonstrated an inhibition of testosterone-induced regrowth of LuCaP35 and LNCaP xenografts by dutasteride (Figure 4B, 4C).

Discussion

Prostate tumors are very heterogeneous in terms of grade, genetics, ploidy, and oncogene/tumor suppressor gene mutation/expression; which translates to tumor heterogeneity in biological, hormonal, and molecular characteristics [28]. Patients whose tumors are not suitable for surgical intervention or radiotherapy are frequently treated by hormonal intervention, either continuous or intermittent androgen deprivation, to suppress prostate cancer cell growth [29-31]. Androgen deprivation initially leads to tumor regression, but invariably, prostate cancer recurs and becomes castration resistant [32, 33]. This is usually accompanied by alterations in the AR in the form of mutations [34, 35], amplification [36], or hypersensitization [37]. Furthermore, recent studies have reported 5α-reductase isozyme differential expression in prostate cancer [38-40]. In one study, decreased expression of 5α-reductase 2 and increased expression of 5α-reductase 1 were observed in prostatic intraepithelial neoplasia (PIN) and prostate cancer [38]. Both 5α-reductase 1 and 2 were increased in high-grade compared to low-grade prostate cancer [41].

In previous studies, we demonstrated that 5α-reductase inhibition through finasteride or dutasteride treatment could prolong the survival of animals bearing LNCaP xenograft tumors on IADT when the off-cycle interval was fixed but not when off-cycle was prolonged. Short interval of off-cycles in the presence of finasteride or dutasteride stimulated prostatic differentiation, but not proliferation. In contrast, prolongation of the off-cycle in the presence of finasteride or dutasteride stimulated both prostatic differentiation and proliferation, with proliferation induction occurring subsequent to differentiation [22]. The inhibition of testosterone-stimulated regrowth by finasteride or dutasteride is associated with enhanced expression of tumor suppressive androgen-response genes such as EAF2, which only occurs during the initial phase but not prolonged regrowth during the off-cycle.

In the current study, LAPC4 xenograft growth was not affected by dutasteride treatment during testosterone replacement. LAPC4 tumors regressed in response to castration while tumors in intact animals continued to grow (Figure 2A). Although tumor growth did not differ between castrated controls and animals treated with dutasteride during testosterone-stimulated regrowth, LAPC4 xenografts in castrated animals had an increased expression of androgen-responsive gene PSA and EAF2 when treated with testosterone replacement (Figure 3). The induction of androgen-response genes during the initial regrowth of regressed tumors suggests that although tumor volume was not
Dutasteride in LAPC4 prostate tumor regrowth

reduced, LAPC4 tumors were sensitive to testosterone during the first 4 days of treatment. However, LAPC4 tumor volume did not respond to dutasteride at 4 days of treatment, whereas LuCaP35 and LNCaP tumors had a statistically significant inhibition in tumor growth by dutasteride or finasteride (Figure 4B). Furthermore, at 14 days of treatment, there was no difference between the LAPC4 tumor xenografts treated with dutasteride plus testosterone and testosterone replacement only (Figure 4C). Both LuCaP35 and LNCaP tumors grew more slowly when treated with 5α-reductase inhibitor during testosterone replacement. These results suggest that tumor response to 5α-reductase inhibition during the off-cycle of IADT is variable in different androgen-sensitive tumors.

In summary, this study showed LAPC4 as a model for prostate cancer xenograft tumor insensitive to 5α-reductase inhibition. One potential mechanism is the inability of dutasteride to enhance the expression of androgen-regulated tumor suppressive genes such as EAF2. Recently, cultured LAPC4 cells were shown to have decreased sensitivity to dutasteride inhibition of AR signaling compared to LNCaP [42]. The ratio of DHT to testosterone varies among prostate cancer cell lines and is much higher in LAPC4 than in LNCaP cells [43], suggesting that the decreased sensitivity of LAPC4 to dutasteride might be due in part to a greater concentration of intracellular DHT.5α-reductase expression was increased in testosterone stimulated LNCaP cells but not in LAPC4 cells [43]. Regressed LAPC4 xenografts were also less sensitive to initial testosterone-stimulated regrowth compared to LuCaP35 and LNCaP tumors (see Figure 4B). Further studies will be required to fully elucidate the mechanisms involved in dutasteride resistance, particularly in testosterone-stimulated regrowth during the off-cycle of IADT. Understanding the mechanisms by which prostate cancer cells respond to or resist dutasteride inhibition of testosterone-induced regrowth may lead to the identification of molecular markers to identify patients who would be benefited from dutasteride administration in IADT.

Acknowledgements

We thank Charles Sawyers and Robert Reiter for LAPC4 cell line and GlaxoSmithKline (GSK) for providing dutasteride and members of Wang lab for critical reading. This study was supported by grants from the National Institute of Health, Prostate Cancer Specialized Program of Research Excellence (SPORE), CA90386 and R37 DK51193. This research was also supported by UPCI Animal Facility funded through NCI CSG P30CA047904. KZM was recipient of a Mellam Fellowship and LEP is a Tippens Fellow.

Disclosure of conflict of interest

Authors have nothing to disclose.

Address correspondence to: Dr. Zhou Wang, Department of Urology, Shadyside Medical Center, Suite G40, 5200 Centre Avenue, Pittsburgh, PA 15232, USA. Tel: 412-623-3903; Fax: 412-623-3904; E-mail: wangz2@upmc.edu

References

Dutasteride in LAPC4 prostate tumor regrowth


Dutasteride in LAPC4 prostate tumor regrowth


